-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STT-003 in Esophageal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STT-003 in Esophageal Cancer Drug Details: STT-003 is under development for the treatment of head...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:Abiraterone acetate (DRGT-45) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-927 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-927 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ABBV-927 in Solid Tumor Drug Details:ABBV-927 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sparsentan in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Sparsentan in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Drug Details:Sparsentan (Filspari) belongs to biphenyls and derivatives....
-
Sector Analysis
IgA Nephropathy (Berger’s Disease) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
IgA Nephropathy Competitive Analysis Report Overview IgA Nephropathy (Berger's disease) is an autoimmune disease that occurs when clumps of antibodies are deposited in the kidneys, causing inflammation and kidney damage. Clumps of IgA and other antibodies damage the glomeruli, tiny blood vessels in the kidneys that filter blood, causing the kidneys to leak blood and protein into the urine. The damage may also lead to scarring of the nephrons, the filtering units where the glomeruli are located. Key Mechanism of...
-
Company Profile
Travere Therapeutics Inc – Company Profile
Travere Therapeutics Inc (Travere Therapeutics), formerly Retrophin Inc, is a biopharmaceutical company that discovers, develops, acquires, and markets drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for therapies to people living with liver, rare kidney and metabolic diseases. Travere Therapeutics pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare...
Add to Basket -
Product Insights
Net Present Value Model: Thiola/Thiola EC
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Thiola/Thiola EC Drug Details Tiopronin (Thiola)...
-
Product Insights
Net Present Value Model: Sparsentan
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Sparsentan Drug Details Sparsentan (RE-021, PS-433540)...
-
Product Insights
Net Present Value Model: Cholbam/Chenodal
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Cholbam/Chenodal Drug Details Cholic acid (Cholbam,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – pegtibatinase
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry pegtibatinase Drug Details Pegtibatinase (OT-58) is under development for the treatment of homocystinuria. It...